I think they have to follow rules on valuation of biological assets. Normally have to pull apart the underlying assumptions as upgrading biological assets and inventory values effectively just brings profit to book sooner and subdues later gains. First glance, I would guess $6-$7m "normalised" next couple of years but I really need to dig through the notes and refine that!
I like that they hint at establishing a div plan. This can be a cashflow business if they don't make the mistakes of last cycle where they didn't hang onto enough financial buffer and got tempted into distracting diversification
I think they have to follow rules on valuation of biological...
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.010(8.00%) |
Mkt cap ! $59.23M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.5¢ | 12.0¢ | $136.7K | 1.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 665 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 63882 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| ATP (ASX) Chart |